Cartesian Therapeutics (RNAC) Stock Forecast & Price Target

$18.87 +2.25 (+13.54%)

(As of 11/22/2024 ET)

Cartesian Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 8 Analyst Ratings

Sell
0

Hold
1

Buy
7

Based on 8 Wall Street analysts who have issued ratings for Cartesian Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 8 analysts, 1 has given a hold rating, and 7 have given a buy rating for RNAC.

Consensus Price Target

$42.33
124.34% Upside

According to the 8 analysts' twelve-month price targets for Cartesian Therapeutics, the average price target is $42.33. The highest price target for RNAC is $50.00, while the lowest price target for RNAC is $39.00. The average price target represents a forecasted upside of 124.34% from the current price of $18.87.

Get the Latest News and Ratings for RNAC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Cartesian Therapeutics and its competitors.

RNAC Analyst Ratings Over Time

Type	Current Forecast 11/26/23 to 11/25/24	1 Month Ago 10/27/23 to 10/26/24	3 Months Ago 8/28/23 to 8/27/24	1 Year Ago 11/26/22 to 11/26/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	N/A
Buy	7 Buy rating(s)	7 Buy rating(s)	7 Buy rating(s)	N/A
Hold	1 Hold rating(s)	1 Hold rating(s)	1 Hold rating(s)	N/A
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	N/A
Consensus Price Target	$42.33	$43.00	$43.00	N/A
Forecasted Upside	124.34% Upside	108.94% Upside	206.27% Upside	N/A
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	N/A

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

RNAC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RNAC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Cartesian Therapeutics Stock vs. The Competition

Type	Cartesian Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.88	2.80	2.50
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	124.34% Upside	27,006.30% Upside	7.66% Upside
News Sentiment Rating	Neutral News See Recent RNAC News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/25/2024	Needham & Company LLC 3 of 5 stars		Reiterated Rating	Buy ➝ Buy	$41.00 ➝ $41.00	+117.28%
11/8/2024	HC Wainwright 2 of 5 stars		Lower Target	Buy ➝ Buy	$45.00 ➝ $41.00	+94.50%
8/6/2024	TD Cowen 4 of 5 stars	T. Van. Buren Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
7/3/2024	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$38.00 ➝ $43.00	+140.90%
7/2/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Outperform ➝ Market Perform
5/24/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$40.00	+57.11%
Trump won. Buy this coin now. (Ad) Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher. This could be his favorite coin.
4/23/2024	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Smith Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
4/23/2024	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$39.00	+113.58%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 08:15 AM ET.

RNAC Forecast - Frequently Asked Questions

: According to the research reports of 8 Wall Street equities research analysts, the average twelve-month stock price forecast for Cartesian Therapeutics is $42.33, with a high forecast of $50.00 and a low forecast of $39.00.
: 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cartesian Therapeutics in the last year. There is currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" RNAC shares.
: According to analysts, Cartesian Therapeutics's stock has a predicted upside of 124.34% based on their 12-month stock forecasts.
: Cartesian Therapeutics has been rated by research analysts at HC Wainwright, and Needham & Company LLC in the past 90 days.
: Analysts like Cartesian Therapeutics more than other "medical" companies. The consensus rating score for Cartesian Therapeutics is 2.88 while the average consensus rating score for "medical" companies is 2.80. Learn more on how RNAC compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

“Fed Proof” Your Bank Account with THESE 4 Simple Steps (Ad)

Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.

Learn these 4 simple steps and protect your savings before it’s too late.

This page (NASDAQ:RNAC) was last updated on 11/25/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cartesian Therapeutics (RNAC) Stock Forecast & Price Target